{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T03:29:58Z","timestamp":1781148598573,"version":"3.54.1"},"reference-count":272,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1097\/nrl.0b013e31823d7abb","type":"journal-article","created":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T00:43:48Z","timestamp":1325810628000},"page":"1-16","source":"Crossref","is-referenced-by-count":69,"title":["Nonmotor Manifestations in Parkinson Disease"],"prefix":"10.1097","volume":"18","author":[{"given":"Oscar","family":"Bernal-Pacheco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natlada","family":"Limotai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Criscely L.","family":"Go","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert H.","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"suppl 3","key":"R1-1-20210211","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00415-009-5240-1","article-title":"Non-motor symptoms in Parkinsons disease.","volume":"256","author":"Park","year":"2009","journal-title":"J Neurol"},{"key":"R2-1-20210211","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1474-4422(09)70068-7","article-title":"Non-motor symptoms of Parkinsons disease: dopaminergic pathophysiology and treatment.","volume":"8","author":"Chaudhuri","year":"2009","journal-title":"Lancet Neurol"},{"key":"R3-1-20210211","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.bandc.2008.07.013","article-title":"The impact of Parkinsons disease on sequence learning: perceptual pattern learning and executive function.","volume":"69","author":"Price","year":"2009","journal-title":"Brain Cogn"},{"key":"R4-1-20210211","first-page":"955","article-title":"Cognitive decline tracks motor progression and not disease duration in Parkinson patients.","volume":"3","author":"Riggeal","year":"2007","journal-title":"Neuropsychiatr Dis Treat"},{"key":"R5-1-20210211","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/archneur.60.3.387","article-title":"Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study.","volume":"60","author":"Aarsland","year":"2003","journal-title":"Arch Neurol"},{"key":"R6-1-20210211","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/mds.21956","article-title":"The Sydney multicenter study of Parkinsons disease: the inevitability of dementia at 20 years.","volume":"23","author":"Hely","year":"2008","journal-title":"Mov Disord"},{"issue":"Part 11","key":"R7-1-20210211","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1093\/brain\/awp234","article-title":"A clinico-pathological study of subtypes in Parkinsons disease.","volume":"132","author":"Selikhova","year":"2009","journal-title":"Brain"},{"key":"R8-1-20210211","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1212\/WNL.0b013e3181d55f61","article-title":"Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo.","volume":"74","author":"Klein","year":"2010","journal-title":"Neurology"},{"key":"R9-1-20210211","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1600-0404.2007.00838.x","article-title":"Dementia in Parkinsons disease: diffusion tensor imaging.","volume":"116","author":"Matsui","year":"2007","journal-title":"Acta Neurol Scand"},{"issue":"suppl 3","key":"R10-1-20210211","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s00415-009-5243-y","article-title":"Formation and development of Lewy pathology: a critical update.","volume":"256","author":"Jellinger","year":"2009","journal-title":"J Neurol"},{"key":"R11-1-20210211","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.parkreldis.2009.11.002","article-title":"Mild cognitive impairment in Parkinsons disease: subtypes and motor characteristics.","volume":"16","author":"Sollinger","year":"2010","journal-title":"Parkinsonism Relat Disord"},{"key":"R12-1-20210211","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/mds.20216","article-title":"Risk and incidence of dementia in a cohort of older subjects with Parkinsons disease in the United Kingdom.","volume":"19","author":"Hobson","year":"2004","journal-title":"Mov Disord"},{"key":"R13-1-20210211","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1001\/archneur.1997.00550150024011","article-title":"Mortality from Parkinson disease.","volume":"54","author":"Louis","year":"1997","journal-title":"Arch Neurol"},{"key":"R14-1-20210211","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/mds.21507","article-title":"Clinical diagnostic criteria for dementia associated with Parkinsons disease.","volume":"22","author":"Emre","year":"2007","journal-title":"Mov Disord"},{"key":"R15-1-20210211","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/mds.20700","article-title":"Long-term benefits of rivastigmine in dementia associated with Parkinsons disease: an active treatment extension study.","volume":"21","author":"Poewe","year":"2006","journal-title":"Mov Disord"},{"key":"R16-1-20210211","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1517\/14740330903439717","article-title":"Safety and tolerability of transdermal and oral rivastigmine in Alzheimers disease and Parkinsons disease dementia.","volume":"9","author":"Darreh-Shori","year":"2010","journal-title":"Expert Opin Drug Saf"},{"key":"R17-1-20210211","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1517\/17425250903105420","article-title":"Rivastigmine in Parkinsons disease dementia.","volume":"5","author":"Chitnis","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R18-1-20210211","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa041470","article-title":"Rivastigmine for dementia associated with Parkinsons disease.","volume":"351","author":"Emre","year":"2004","journal-title":"N Engl J Med"},{"key":"R19-1-20210211","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1136\/jnnp.2004.050682","article-title":"Donepezil for dementia in Parkinsons disease: a randomised, double blind, placebo controlled, crossover study.","volume":"76","author":"Ravina","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R21-1-20210211","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s11055-008-9077-3","article-title":"Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinsons disease (an open controlled trial).","volume":"38","author":"Litvinenko","year":"2008","journal-title":"Neurosci Behav Physiol"},{"key":"R22-1-20210211","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/jnnp.2008.144048","article-title":"A double-blind comparison of galantamine hydrobromide ER and placebo in Parkinson disease.","volume":"80","author":"Grace","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R23-1-20210211","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S1474-4422(09)70146-2","article-title":"Memantine in patients with Parkinsons disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial.","volume":"8","author":"Aarsland","year":"2009","journal-title":"Lancet Neurol"},{"key":"R24-1-20210211","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/mds.22495","article-title":"Randomized controlled trial of memantine in dementia associated with Parkinsons disease.","volume":"24","author":"Leroi","year":"2009","journal-title":"Mov Disord"},{"key":"R25-1-20210211","first-page":"273","article-title":"Effect of memantine (NMDA antagonist) on Parkinsons disease: a double-blind crossover randomized study.","volume":"22","author":"Merello","year":"1999","journal-title":"Clin Neuropharmacol"},{"key":"R26-1-20210211","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11055-009-9244-1","article-title":"Use of memantine (akatinol) for the correction of cognitive impairments in Parkinsons disease complicated by dementia.","volume":"40","author":"Litvinenko","year":"2010","journal-title":"Neurosci Behav Physiol"},{"issue":"part 4","key":"R27-1-20210211","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/brain\/123.4.733","article-title":"Hallucination in Parkinsons disease: prevalence, phenomenology, and risk factor.","volume":"123","author":"Fenelon","year":"2000","journal-title":"Brain"},{"key":"R28-1-20210211","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/mds.20324","article-title":"Sydney multicenter study of Parkinsons disease: non-L-dopa-responsive problem dominate at 15 years.","volume":"20","author":"Hely","year":"2005","journal-title":"Mov Disord"},{"key":"R29-1-20210211","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1212\/WNL.43.11.2227","article-title":"Risk factors for nursing home placement in advanced Parkinsons disease.","volume":"43","author":"Goetz","year":"1993","journal-title":"Neurology"},{"key":"R30-1-20210211","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/jnnp.70.6.727","article-title":"Visual hallucination in Parkinsons disease: a review and phenomenological survey.","volume":"70","author":"Barnes","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R31-1-20210211","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/archneur.56.5.595","article-title":"Prevalence and clinical correlates of psychotic symptoms in Parkinsons disease: a community-based study.","volume":"56","author":"Aarsland","year":"1999","journal-title":"Arch Neurol"},{"key":"R32-1-20210211","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/mds.20263","article-title":"Hallucinations in Parkinsons disease: a follow-up study.","volume":"20","author":"De Maindreville","year":"2005","journal-title":"Mov Disord"},{"key":"R33-1-20210211","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1136\/jnnp.70.6.734","article-title":"Prospective study of hallucinations and delusions in Parkinsons disease.","volume":"70","author":"Holroyd","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R34-1-20210211","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/mds.22453","article-title":"Psychotic and compulsive syndrome in Parkinsons disease.","volume":"24","author":"Verbaan","year":"2009","journal-title":"Mov Disord"},{"key":"R35-1-20210211","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s00415-005-0840-x","article-title":"Factors associated with drug-induced visual hallucinations in Parkinsons disease.","volume":"252","author":"Papapetropoulos","year":"2005","journal-title":"J Neurol"},{"key":"R36-1-20210211","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s007020050005","article-title":"Risk factors for dementia, depression, and psychosis in long-standing Parkinsons disease.","volume":"107","author":"Giladi","year":"2000","journal-title":"J Neural Transm"},{"key":"R37-1-20210211","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/mds.21382","article-title":"Diagnostic criteria for psychosis in Parkinsons disease: report of an NINDS NIMH work group.","volume":"22","author":"Ravina","year":"2007","journal-title":"Mov Disord"},{"key":"R38-1-20210211","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1212\/01.WNL.0000129843.15756.A3","article-title":"Psychiatric comorbidities in patients with Parkinson disease and psychosis.","volume":"63","author":"Marsh","year":"2004","journal-title":"Neurology"},{"key":"R39-1-20210211","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/jnnp.64.4.533","article-title":"Auditory hallucinations in Parkinsons disease.","volume":"64","author":"Inzelberg","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R40-1-20210211","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.wnf.0000144040.20600.c1","article-title":"Threatening auditory hallucinations and Cotard syndrome in Parkinson disease.","volume":"27","author":"Factor","year":"2004","journal-title":"Clin Neuropharmacol"},{"key":"R41-1-20210211","first-page":"447","article-title":"Levodopa-induced psychosis.","volume":"8","author":"Kalwans","year":"1978","journal-title":"Psychiatr Ann"},{"key":"R42-1-20210211","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11940-004-0010-y","article-title":"Psychosis in Parkinsons disease.","volume":"6","author":"Marsh","year":"2004","journal-title":"Curr Treat Option Neurol"},{"key":"R43-1-20210211","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/mds.10450","article-title":"Coping strategies for visual hallucination in Parkinsons disease.","volume":"18","author":"Diederich","year":"2003","journal-title":"Mov Disord"},{"key":"R44-1-20210211","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s00415-006-0388-4","article-title":"Relationship between age and subtypes of psychotic symptoms in Parkinsons disease.","volume":"254","author":"Kiziltan","year":"2007","journal-title":"J Neurol"},{"key":"R45-1-20210211","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1002\/mds.20582","article-title":"Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinsons disease.","volume":"20","author":"Pacchetti","year":"2005","journal-title":"Mov Disord"},{"key":"R46-1-20210211","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1176\/ajp.135.6.669","article-title":"Levodopa-induced psychosis: a kindling phenomenon.","volume":"135","author":"Moskovitz","year":"1978","journal-title":"Am J Psychiatry"},{"key":"R47-1-20210211","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/1531-8257(199901)14:1<117::AID-MDS1019>3.0.CO;2-0","article-title":"Sleep fragmentation, and altered dream phenomena in PD.","volume":"14","author":"Pappert","year":"1999","journal-title":"Mov Disord"},{"key":"R48-1-20210211","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1212\/01.WNL.0000148479.10865.FE","article-title":"Hallucinations and sleep disorders in PD: six-year prospective longitudinal study.","volume":"6","author":"Goetz","year":"2005","journal-title":"Neurology"},{"key":"R50-1-20210211","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1002\/mds.22099","article-title":"Manifestations of PD differ in association with REM sleep behavior disorder.","volume":"23","author":"Postuma","year":"2008","journal-title":"Mov Disord"},{"key":"R51-1-20210211","doi-asserted-by":"crossref","first-page":"513","DOI":"10.4088\/JCP.v63n0608","article-title":"Quetiapine use for psychosis in Parkinsons disease versus dementia with Lewy bodies.","volume":"63","author":"Fernandez","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"R52-1-20210211","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2165\/00002018-200326090-00004","article-title":"The treatment of psychosis in Parkinsons disease: safety and considerations.","volume":"26","author":"Fernandez","year":"2003","journal-title":"Drug Safety"},{"key":"R53-1-20210211","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/mds.20051","article-title":"Long-term outcome of clozapine use for psychosis in Parkinsons patients.","volume":"19","author":"Fernandez","year":"2004","journal-title":"Mov Disord"},{"key":"R54-1-20210211","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2165\/00002512-200825080-00004","article-title":"Pathophysiology and treatment of psychosis in Parkinsons disease.","volume":"25","author":"Zahodne","year":"2008","journal-title":"Drugs Aging"},{"key":"R55-1-20210211","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1212\/01.wnl.0000215428.46057.3d","article-title":"Practice parameter: evaluation and treatment of depression, psychosis and dementia in Parkinsons disease (an-evidence base review): report of the Quality Standards Subcomittee of the American Academy of Neurology.","volume":"66","author":"Miyasaki","year":"2006","journal-title":"Neurology"},{"key":"R56-1-20210211","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S0140-6736(94)92511-9","article-title":"Risperidone for hallucinations in levodopa-treated Parkinsons disease patients.","volume":"343","author":"Meco","year":"1994","journal-title":"Lancet"},{"key":"R57-1-20210211","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1176\/jnp.9.4.594","article-title":"The use of risperidone for psychosis and agitation in demented patients with Parkinsons disease.","volume":"9","author":"Workman","year":"1997","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"R58-1-20210211","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/1531-8257(200011)15:6<1230::AID-MDS1026>3.0.CO;2-9","article-title":"Risperidone in the treatment of dopamine-induced psychosis in Parkinsons disease: an open pilot trial.","volume":"15","author":"Mohr","year":"2000","journal-title":"Mov Disord"},{"key":"R59-1-20210211","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/070674370404900119","article-title":"Ziprasidone in Parkinsons disease psychosis letter.","volume":"49","author":"Connemann","year":"2004","journal-title":"Can J Psychiatry"},{"key":"R60-1-20210211","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.eurpsy.2005.05.005","article-title":"Ziprasidone in the treatment of Parkinsons disease psychosis.","volume":"21","author":"Shiah","year":"2006","journal-title":"Eur Psychiatry"},{"key":"R61-1-20210211","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/00002826-200401000-00003","article-title":"Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience.","volume":"27","author":"Fernandez","year":"2004","journal-title":"Clin Neuropharmacol"},{"key":"R62-1-20210211","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1002\/mds.21091","article-title":"Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinsons disease.","volume":"21","author":"Friedman","year":"2006","journal-title":"Mov Disord"},{"key":"R63-1-20210211","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(00)03399-7","article-title":"Efficacy of rivastigmine in dementia of Lewy bodies: a randomized, double-blinded, placebo-controlled international study.","volume":"356","author":"McKeith","year":"2000","journal-title":"Lancet"},{"key":"R64-1-20210211","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/mds.1204","article-title":"Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary finding from an open trial.","volume":"16","author":"Reading","year":"2001","journal-title":"Mov Disord"},{"key":"R65-1-20210211","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/00002826-200203000-00009","article-title":"Successful use of donepezil for the treatment of the psychotic symptoms in patients with Parkinsons disease.","volume":"25","author":"Bergman","year":"2002","journal-title":"Clin Neuropharmacol"},{"key":"R66-1-20210211","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1136\/jnnp.2004.050682","article-title":"Donepezil for dementia in Parkinsons disease: a randomised, double blind, placebo controlled, crossover study.","volume":"76","author":"Ravina","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R67-1-20210211","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S1474-4422(09)70146-2","article-title":"Memantine in patients with Parkinsons disease dementia or dementia of Lewy bodies: a double-blind, placebo-controlled, multicentre trial.","volume":"8","author":"Aarslanad","year":"2009","journal-title":"Lancet Neurol"},{"key":"R68-1-20210211","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jocn.2009.09.001","article-title":"Impulsive smoking in a patient with Parkinsons disease treated with dopamine agonists.","volume":"17","author":"Bienfait","year":"2010","journal-title":"J Clin Neurosci"},{"key":"R69-1-20210211","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archneurol.2010.65","article-title":"Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients.","volume":"67","author":"Weintraub","year":"2010","journal-title":"Arch Neurol"},{"key":"R70-1-20210211","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00213-009-1697-y","article-title":"Impulsive choice and response in dopamine agonist-related impulse control behaviors.","volume":"207","author":"Voon","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"key":"R71-1-20210211","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/mds.21872","article-title":"The relationship between impulsivity and impulse control disorders in Parkinsons disease.","volume":"23","author":"Isaias","year":"2008","journal-title":"Mov Disord"},{"key":"R72-1-20210211","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1212\/01.wnl.0000238401.76928.45","article-title":"Clinical features associated with impulse control disorders in Parkinson disease.","volume":"67","author":"Pontone","year":"2006","journal-title":"Neurology"},{"issue":"suppl 4","key":"R73-1-20210211","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1016\/S1353-8020(09)70847-8","article-title":"Impulse control disorders in Parkinsons disease: definition, epidemiology, risk factors, neurobiology and management.","volume":"15","author":"Ceravolo","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"R74-1-20210211","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/ana.20822","article-title":"Compulsive drug use linked to sensitized ventral striatal dopamine transmission.","volume":"59","author":"Evans","year":"2006","journal-title":"Ann Neurol"},{"issue":"suppl 4","key":"R75-1-20210211","first-page":"14","article-title":"Kleptomania, compulsive buying, and binge-eating disorder.","volume":"56","author":"McElroy","year":"1995","journal-title":"J Clin Psychiatry"},{"key":"R76-1-20210211","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1176\/ajp.149.3.318","article-title":"The DSM-III-R impulse control disorders not elsewhere classified: clinical characteristics and relationship to other psychiatric disorders.","volume":"149","author":"McElroy","year":"1992","journal-title":"Am J Psychiatry"},{"key":"R77-1-20210211","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1212\/01.wnl.0000218206.20920.4d","article-title":"Prospective prevalence of pathologic gambling and medication association in Parkinson disease.","volume":"66","author":"Voon","year":"2006","journal-title":"Neurology"},{"key":"R78-1-20210211","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1002\/mds.21110","article-title":"Problematic gambling on dopamine agonists: not such a rarity.","volume":"21","author":"Grosset","year":"2006","journal-title":"Mov Disord"},{"key":"R79-1-20210211","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2147\/nedt.2007.3.1.161","article-title":"The four As associated with pathological Parkinson disease gamblers: anxiety, anger, age, and agonists.","volume":"3","author":"Shapiro","year":"2007","journal-title":"Neuropsychiatr Dis Treat"},{"key":"R80-1-20210211","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.neuron.2009.12.027","article-title":"Mechanisms underlying dopamine-mediated reward bias in compulsive behaviors.","volume":"65","author":"Voon","year":"2010","journal-title":"Neuron"},{"key":"R81-1-20210211","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1532-5415.1977.tb00415.x","article-title":"Increased appetite (bulimia) in Parkinsons disease.","volume":"25","author":"Rosenberg","year":"1977","journal-title":"J Am Geriatr Soc"},{"key":"R82-1-20210211","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/mds.20757","article-title":"Compulsive eating and weight gain related to dopamine agonist use.","volume":"21","author":"Nirenberg","year":"2006","journal-title":"Mov Disord"},{"key":"R83-1-20210211","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1176\/appi.neuropsych.23.1.56","article-title":"Binge eating in PD: prevalence, correlates, and the contribution of deep brain stimulation surgery.","volume":"23","author":"Zahodne","year":"2011","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"R84-1-20210211","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2147\/IJGM.S4674","article-title":"Prevalence of hypersexual behavior in Parkinsons disease patients: not restricted to males and dopamine agonist use.","volume":"2","author":"Cooper","year":"2009","journal-title":"Int J Gen Med"},{"key":"R85-1-20210211","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/mds.870130338","article-title":"Clozapine for dopaminergic-induced paraphilias in Parkinsons disease.","volume":"13","author":"Fernandez","year":"1998","journal-title":"Mov Disord"},{"key":"R86-1-20210211","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1002\/mds.22848","article-title":"Pramipexole and gender identity disorder: expanding the phenotype of hypersexuality in Parkinsons disease.","volume":"24","author":"Odiyoor","year":"2009","journal-title":"Mov Disord"},{"key":"R87-1-20210211","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.parkreldis.2006.01.010","article-title":"Hypersexuality and paraphilia induced by selegiline in Parkinsons disease: report of 2 cases.","volume":"12","author":"Shapiro","year":"2006","journal-title":"Parkinsonism Relat Disord"},{"key":"R88-1-20210211","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/S1474-4422(09)70287-X","article-title":"Chronic dopaminergic stimulation in Parkinsons disease: from dyskinesias to impulse control disorders.","volume":"8","author":"Voon","year":"2009","journal-title":"Lancet Neurol"},{"key":"R89-1-20210211","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/1531-8257(199909)14:5<836::AID-MDS1018>3.0.CO;2-0","article-title":"Punding on L-dopa.","volume":"14","author":"Fernandez","year":"1999","journal-title":"Mov Disord"},{"key":"R90-1-20210211","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2165\/00023210-200923020-00005","article-title":"Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management.","volume":"23","author":"OSullivan","year":"2009","journal-title":"CNS Drugs"},{"key":"R91-1-20210211","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/gps.2324","article-title":"Prevalence and characteristics of punding and repetitive behaviors among Parkinson patients in North-Central Florida.","volume":"25","author":"Nguyen","year":"2010","journal-title":"Int J Geriatr Psychiatry"},{"key":"R92-1-20210211","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.parkreldis.2010.02.006","article-title":"Long term follow-up of Parkinsons disease patients with impulse control disorders.","volume":"16","author":"Sohtaoglu","year":"2010","journal-title":"Parkinsonism Relat Disord"},{"key":"R93-1-20210211","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2165\/00002018-200932060-00004","article-title":"Behavioural adverse effects of dopaminergic treatments in Parkinsons disease: incidence, neurobiological basis, management and prevention.","volume":"32","author":"Antonini","year":"2009","journal-title":"Drug Saf"},{"key":"R94-1-20210211","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.parkreldis.2003.08.002","article-title":"Stereotyped behaviors or punding after quetiapine administration in Parkinsons disease.","volume":"10","author":"Miwa","year":"2004","journal-title":"Parkinsonism Relat Disord"},{"key":"R95-1-20210211","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement Disorder Society-sponsored revision of the Unified Parkinsons Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov Disord"},{"key":"R96-1-20210211","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/mds.20045","article-title":"Punding in Parkinsons disease: its relation to the dopamine dysregulation syndrome.","volume":"19","author":"Evans","year":"2004","journal-title":"Mov Disord"},{"key":"R97-1-20210211","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1017\/S0317167100009665","article-title":"Depression in Parkinsons disease.","volume":"37","author":"Jasinska-Myga","year":"2010","journal-title":"Can J Neurol Sci"},{"key":"R98-1-20210211","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/1531-8257(200007)15:4<669::AID-MDS1011>3.0.CO;2-5","article-title":"Anxiety disorders and depressive disorders preceding Parkinsons disease: a case-control study.","volume":"15","author":"Shiba","year":"2000","journal-title":"Mov Disord"},{"key":"R99-1-20210211","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1002\/mds.22285","article-title":"Clinical correlates of depressive symptoms in familial Parkinsons disease.","volume":"23","author":"Pankratz","year":"2008","journal-title":"Mov Disord"},{"key":"R100-1-20210211","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/0891988709335792","article-title":"Depressive symptoms in Parkinson disease correlate with impaired global and specific cognitive performance.","volume":"22","author":"Fernandez","year":"2009","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"R101-1-20210211","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1017\/S0033291700001872","article-title":"Depression and disability in Parkinsons disease: a follow-up of 132 cases.","volume":"18","author":"Brown","year":"1988","journal-title":"Psychol Med"},{"key":"R102-1-20210211","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/mds.21866","article-title":"A validation study of depressive syndromes in Parkinsons disease.","volume":"23","author":"Starkstein","year":"2008","journal-title":"Mov Disord"},{"key":"R103-1-20210211","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0033-3182(10)70655-1","article-title":"Prevalence and characteristics of alexithymia in Parkinsons disease.","volume":"51","author":"Costa","year":"2010","journal-title":"Psychosomatics"},{"key":"R104-1-20210211","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/gps.1456","article-title":"Depressive symptom profile in Parkinsons disease: a comparison with depression in elderly patients without Parkinsons disease.","volume":"21","author":"Ehrt","year":"2006","journal-title":"Int J Geriatr Psychiatry"},{"key":"R105-1-20210211","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S1353-8020(01)00015-3","article-title":"Non-recognition of depression and other non-motor symptoms in Parkinsons disease.","volume":"8","author":"Shulman","year":"2002","journal-title":"Parkinsonism Relat Disord"},{"key":"R106-1-20210211","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10072-008-1021-3","article-title":"Sertraline in the treatment of depressive disorders in patients with Parkinsons disease.","volume":"29","author":"Marino","year":"2008","journal-title":"Neurol Sci"},{"key":"R107-1-20210211","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1524-4733.2010.00729.x","article-title":"Cost-Effectiveness of Duloxetine: The Stress Urinary Incontinence Treatment (SUIT) Study.","volume":"13","author":"Mihaylova","year":"2010","journal-title":"Value Health"},{"key":"R108-1-20210211","first-page":"1010","article-title":"A comparison between low doses of amitriptyline and low doses of fluoxetin used in the control of depression in patients suffering from Parkinsons disease.","volume":"35","author":"Serrano-Duenas","year":"2002","journal-title":"Rev Neurol"},{"key":"R109-1-20210211","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/mds.20895","article-title":"Randomized study of sertraline and low-dose amitriptyline in patients with Parkinsons disease and depression: effect on quality of life.","volume":"21","author":"Antonini","year":"2006","journal-title":"Mov Disord"},{"key":"R110-1-20210211","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/mds.21966","article-title":"Comparison of desipramine and citalopram treatments for depression in Parkinsons disease: a double-blind, randomized, placebo-controlled study.","volume":"23","author":"Devos","year":"2008","journal-title":"Mov Disord"},{"key":"R111-1-20210211","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1212\/01.wnl.0000336340.89821.b3","article-title":"A controlled trial of antidepressants in patients with Parkinson disease and depression.","volume":"72","author":"Menza","year":"2009","journal-title":"Neurology"},{"key":"R113-1-20210211","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1474-4422(10)70106-X","article-title":"Pramipexole for the treatment of depressive symptoms in patients with Parkinsons disease: a randomised, double-blind, placebo-controlled trial.","volume":"9","author":"Barone","year":"2010","journal-title":"Lancet Neurol"},{"key":"R114-1-20210211","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00415-006-0067-5","article-title":"Pramipexole versus sertraline in the treatment of depression in Parkinsons disease: a national multicenter parallel-group randomized study.","volume":"253","author":"Barone","year":"2006","journal-title":"J Neurol"},{"key":"R115-1-20210211","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/WNF.0b013e31815d25ce","article-title":"Effects of ropinirole on nonmotor symptoms of Parkinson disease: a prospective multicenter study.","volume":"31","author":"Rektorova","year":"2008","journal-title":"Clin Neuropharmacol"},{"key":"R116-1-20210211","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/j.clinph.2007.07.010","article-title":"An open study of repetitive transcranial magnetic stimulation in treatment-resistant depression with Parkinsons disease.","volume":"118","author":"Epstein","year":"2007","journal-title":"Clin Neurophysiol"},{"key":"R117-1-20210211","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1212\/01.wnl.0000218194.12054.60","article-title":"Effects of antidepressant treatment with rTMS and fluoxetine on brain perfusion in PD.","volume":"66","author":"Fregni","year":"2006","journal-title":"Neurology"},{"issue":"suppl 1","key":"R119-1-20210211","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.parkreldis.2004.02.002","article-title":"Treatment of depression in Parkinsons disease.","volume":"10","author":"Sawabini","year":"2004","journal-title":"Parkinsonism Relat Disord"},{"key":"R120-1-20210211","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1756-0500-3-60","article-title":"Deep brain stimulation for obsessive-compulsive disorder and treatment-resistant depression: systematic review.","volume":"3","author":"Lakhan","year":"2010","journal-title":"BMC Res Notes"},{"key":"R121-1-20210211","first-page":"42","article-title":"Anxiety disorders in Parkinsons disease.","volume":"96","author":"Richard","year":"2005","journal-title":"Adv Neurol"},{"key":"R122-1-20210211","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1176\/jnp.2009.21.4.413","article-title":"Anxiety, depression, and quality of life in Parkinsons disease.","volume":"21","author":"Quelhas","year":"2009","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"R123-1-20210211","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/089198879901200202","article-title":"Depression and anxiety in Parkinsons disease: possible effect of genetic variation in the serotonin transporter.","volume":"12","author":"Menza","year":"1999","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"R124-1-20210211","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1176\/ajp.148.2.274b","article-title":"Anxiety disorders in familial parkinsonism.","volume":"148","author":"Lauterbach","year":"1991","journal-title":"Am J Psychiatry"},{"key":"R125-1-20210211","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1212\/WNL.59.3.408","article-title":"Nonmotor fluctuations in Parkinsons disease: frequent and disabling.","volume":"59","author":"Witjas","year":"2002","journal-title":"Neurology"},{"key":"R128-1-20210211","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1007\/s00415-008-0955-y","article-title":"Neuropsychiatric symptoms three years after subthalamic DBS in PD patients: a case-control study.","volume":"255","author":"Castelli","year":"2008","journal-title":"J Neurol"},{"key":"R129-1-20210211","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1136\/jnnp.73.6.636","article-title":"Apathy in Parkinsons disease.","volume":"73","author":"Pluck","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R130-1-20210211","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1212\/01.wnl.0000230572.07791.22","article-title":"Dissociating apathy and depression in Parkinson disease.","volume":"67","author":"Kirsch-Darrow","year":"2006","journal-title":"Neurology"},{"key":"R131-1-20210211","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/cercor\/bhj043","article-title":"Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits.","volume":"16","author":"Levy","year":"2006","journal-title":"Cereb Cortex"},{"key":"R132-1-20210211","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1136\/jnnp.2008.170043","article-title":"Occurrence and risk factors for apathy in Parkinson disease: a 4-year prospective longitudinal study.","volume":"80","author":"Pedersen","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R133-1-20210211","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00415-009-5297-x","article-title":"Apathy in drug-naive patients with incident Parkinsons disease: the Norwegian ParkWest study.","volume":"257","author":"Pedersen","year":"2010","journal-title":"J Neurol"},{"key":"R134-1-20210211","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/mds.10041","article-title":"Clinical, neuropsychological, and morphometric correlates of apathy in Parkinsons disease.","volume":"17","author":"Isella","year":"2002","journal-title":"Mov Disord"},{"key":"R135-1-20210211","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s11055-008-9077-3","article-title":"Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinsons disease (an open controlled trial).","volume":"38","author":"Litvinenko","year":"2008","journal-title":"Neurosci Behav Physiol"},{"key":"R136-1-20210211","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1016\/S0028-3932(02)00108-2","article-title":"Motivation, reward, and Parkinsons disease: influence of dopatherapy.","volume":"40","author":"Czernecki","year":"2002","journal-title":"Neuropsychologia"},{"key":"R138-1-20210211","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.jocn.2009.09.043","article-title":"Successful treatment of post-stroke apathy by the dopamine receptor agonist ropinirole.","volume":"17","author":"Kohno","year":"2010","journal-title":"J Clin Neurosci"},{"issue":"suppl 1","key":"R139-1-20210211","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s10286-007-1001-3","article-title":"Prevalence of orthostatic hypotension.","volume":"18","author":"Low","year":"2008","journal-title":"Clin Auton Res"},{"key":"R140-1-20210211","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jns.2009.08.031","article-title":"Cardiovascular autonomic dysfunction in Parkinsons disease.","volume":"289","author":"Ziemssen","year":"2010","journal-title":"J Neurol Sci"},{"key":"R141-1-20210211","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/mds.22457","article-title":"Orthostatic hypotension, balance and falls in Parkinsons disease.","volume":"24","author":"Matinolli","year":"2009","journal-title":"Mov Disord"},{"key":"R142-1-20210211","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1474-4422(08)70088-7","article-title":"Management of neurogenic orthostatic hypotension: an update.","volume":"7","author":"Low","year":"2008","journal-title":"Lancet Neurol"},{"key":"R143-1-20210211","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/mds.21422","article-title":"Sweating in Parkinsonian patients with wearing-off.","volume":"22","author":"Pursiainen","year":"2007","journal-title":"Mov Disord"},{"key":"R144-1-20210211","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1002\/mds.10586","article-title":"Sweating dysfunction in Parkinsons disease.","volume":"18","author":"Swinn","year":"2003","journal-title":"Mov Disord"},{"issue":"suppl 7","key":"R145-1-20210211","first-page":"VII42","article-title":"Sweating dysfunctions in Parkinsons disease.","volume":"253","author":"Hirayama","year":"2006","journal-title":"J Neurol"},{"key":"R147-1-20210211","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/WNF.0b013e31816d91f9","article-title":"Open-label study assessment of safety and adverse effects of subcutaneous apomorphine injections in treating off episodes in advanced Parkinson disease.","volume":"32","author":"LeWitt","year":"2009","journal-title":"Clin Neuropharmacol"},{"key":"R148-1-20210211","first-page":"1741","article-title":"Swallowing and esophageal function in Parkinsons disease.","volume":"90","author":"Johnston","year":"1995","journal-title":"Am J Gastroenterol"},{"key":"R149-1-20210211","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1212\/WNL.42.4.726","article-title":"Gastrointestinal dysfunction in Parkinsons disease: frequency and pathophysiology.","volume":"42","author":"Edwards","year":"1992","journal-title":"Neurology"},{"key":"R150-1-20210211","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/mds.20189","article-title":"Salivary production in Parkinsons disease.","volume":"20","author":"Proulx","year":"2005","journal-title":"Mov Disord"},{"key":"R151-1-20210211","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s00415-007-0508-9","article-title":"Impact of drooling in Parkinsons disease.","volume":"254","author":"Kalf","year":"2007","journal-title":"J Neurol"},{"key":"R152-1-20210211","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.parkreldis.2009.12.003","article-title":"The impact of and the factors associated with drooling in Parkinsons disease.","volume":"16","author":"Leibner","year":"2010","journal-title":"Parkinsonism Relat Disord"},{"key":"R153-1-20210211","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/mds.20793","article-title":"Botulinum toxin type A for drooling in Parkinsons disease: a double-blind, randomized, placebo-controlled study.","volume":"21","author":"Lagalla","year":"2006","journal-title":"Mov Disord"},{"key":"R154-1-20210211","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00415-009-0085-1","article-title":"Long-lasting benefits of botulinum type B in Parkinsons disease-related drooling.","volume":"256","author":"Lagalla","year":"2009","journal-title":"J Neurol"},{"key":"R155-1-20210211","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1212\/WNL.0b013e3181d8c1b7","article-title":"Glycopyrrolate for sialorrhea in Parkinson disease: a randomized, double-blind, crossover trial.","volume":"74","author":"Arbouw","year":"2010","journal-title":"Neurology"},{"key":"R156-1-20210211","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrneurol.2010.107","article-title":"Parkinson disease: sialorrhea and Parkinson diseasenovel treatment approaches.","volume":"6","author":"Troche","year":"2010","journal-title":"Nat Rev Neurol"},{"key":"R157-1-20210211","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1002\/mds.21730","article-title":"Ipratropium bromide spray as treatment for sialorrhea in Parkinsons disease.","volume":"22","author":"Thomsen","year":"2007","journal-title":"Mov Disord"},{"key":"R158-1-20210211","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.2165\/0002512-200825120-00003","article-title":"Sialorrhoea and drooling in patients with Parkinsons disease: epidemiology and management.","volume":"25","author":"Merello","year":"2008","journal-title":"Drugs Aging"},{"key":"R159-1-20210211","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1002\/mds.21752","article-title":"Radiotherapy to the salivary glands as treatment of sialorrhea in patients with parkinsonism.","volume":"22","author":"Postma","year":"2007","journal-title":"Mov Disord"},{"key":"R160-1-20210211","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1212\/WNL.0b013e3181d9002b","article-title":"Gum chewing improves swallow frequency and latency in Parkinson patients: a preliminary study.","volume":"74","author":"South","year":"2010","journal-title":"Neurology"},{"key":"R161-1-20210211","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.autneu.2009.04.004","article-title":"Hyposialorrhea as an early manifestation of Parkinson disease.","volume":"150","author":"Cersosimo","year":"2009","journal-title":"Auton Neurosci"},{"key":"R165-1-20210211","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3109\/00207450903337721","article-title":"The relationship between anosmia, constipation, and orthostasis and Parkinsons disease duration: results of a pilot study.","volume":"120","author":"Ramjit","year":"2010","journal-title":"Int J Neurosci"},{"key":"R166-1-20210211","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3109\/00207451003615755","article-title":"Is rhinorrhea an under-recognized intrinsic symptom of Parkinson disease A prospective pilot study.","volume":"120","author":"Sedig","year":"2010","journal-title":"Int J Neurosci"},{"key":"R167-1-20210211","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/mds.21869","article-title":"Rhinorrhea is increased in Parkinsons disease.","volume":"23","author":"Friedman","year":"2008","journal-title":"Mov Disord"},{"key":"R168-1-20210211","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/mds.23366","article-title":"Rhinorrhea: a common nondopaminergic feature of Parkinsons disease.","volume":"26","author":"Chou","year":"2011","journal-title":"Mov Disord"},{"key":"R169-1-20210211","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1212\/WNL.0b013e3181bf992f","article-title":"Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort.","volume":"73","author":"Uc","year":"2009","journal-title":"Neurology"},{"key":"R170-1-20210211","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/archneur.1989.00520460037010","article-title":"Anal sphincter dysfunction in Parkinsons disease.","volume":"46","author":"Mathers","year":"1989","journal-title":"Arch Neurol"},{"key":"R171-1-20210211","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/mds.22051","article-title":"Neural control of the gastrointestinal tract: implications for Parkinson disease.","volume":"23","author":"Cersosimo","year":"2008","journal-title":"Mov Disord"},{"key":"R172-1-20210211","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1002\/mds.22705","article-title":"Major nutritional issues in the management of Parkinsons disease.","volume":"24","author":"Barichella","year":"2009","journal-title":"Mov Disord"},{"issue":"suppl 2","key":"R173-1-20210211","first-page":"S55","article-title":"Digestive disorders in Parkinsons disease: gastric atony, malabsorption and constipation.","volume":"50","author":"Perez-Macho","year":"2010","journal-title":"Rev Neurol"},{"key":"R174-1-20210211","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/mds.21243","article-title":"Macrogol for the treatment of constipation in Parkinsons disease. A randomized placebo-controlled study.","volume":"22","author":"Zangaglia","year":"2007","journal-title":"Mov Disord"},{"key":"R175-1-20210211","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/mds.870120524","article-title":"Severe constipation in Parkinsons disease relieved by botulinum toxin.","volume":"12","author":"Albanese","year":"1997","journal-title":"Mov Disord"},{"key":"R176-1-20210211","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/ana.410330512","article-title":"Defecatory function in Parkinsons disease: response to apomorphine.","volume":"33","author":"Edwards","year":"1993","journal-title":"Ann Neurol"},{"key":"R177-1-20210211","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/mds.22596","article-title":"Intrajejunal levodopa infusion in Parkinsons disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.","volume":"24","author":"Honigo","year":"2009","journal-title":"Mov Disord"},{"key":"R178-1-20210211","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/mds.21586","article-title":"Prevalence of nonmotor symptoms in Parkinsons disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients.","volume":"22","author":"Martinez-Martin","year":"2007","journal-title":"Mov Disord"},{"key":"R180-1-20210211","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1136\/jnnp.2009.186239","article-title":"Use of drugs with anticholinergic effect and impact on cognition in Parkinsons disease: a cohort study.","volume":"81","author":"Ehrt","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R181-1-20210211","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1111\/j.1742-1241.2008.01849.x","article-title":"Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin.","volume":"62","author":"Kay","year":"2008","journal-title":"Int J Clin Pract"},{"key":"R182-1-20210211","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.juro.2009.06.023","article-title":"Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinsons disease and multiple system atrophy.","volume":"182","author":"Giannantoni","year":"2009","journal-title":"J Urol"},{"key":"R183-1-20210211","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.neuroscience.2009.06.001","article-title":"Biphasic effect of apomorphine, an anti-parkinsonian drug, on bladder function in rats.","volume":"162","author":"Uchiyama","year":"2009","journal-title":"Neuroscience"},{"key":"R184-1-20210211","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(88)90932-4","article-title":"Role of subcutaneous apomorphine in parkinsonian voiding dysfunction.","volume":"2","author":"Christmas","year":"1988","journal-title":"Lancet"},{"key":"R185-1-20210211","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/j.1743-6109.2008.01083.x","article-title":"Loss of libido in Parkinsons disease.","volume":"6","author":"Kummer","year":"2009","journal-title":"J Sex Med"},{"key":"R186-1-20210211","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1159\/000052503","article-title":"Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction.","volume":"39","author":"Dula","year":"2001","journal-title":"Eur Urol"},{"key":"R187-1-20210211","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1136\/jnnp.72.5.681","article-title":"Apomorphine as an alternative to sildenafil in Parkinsons disease.","volume":"72","author":"OSullivan","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R188-1-20210211","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1136\/jnnp.71.3.371","article-title":"Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinsons disease or multiple system atrophy with observations on orthostatic hypotension.","volume":"71","author":"Hussain","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R189-1-20210211","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2165\/00002512-200219100-00002","article-title":"Sleep disorders in Parkinsons disease: epidemiology and management.","volume":"19","author":"Stacy","year":"2002","journal-title":"Drug Aging"},{"key":"R190-1-20210211","first-page":"329","article-title":"Sleep disorders in Parkinsons disease.","volume":"91","author":"Larsen","year":"2003","journal-title":"Adv Neurol"},{"key":"R191-1-20210211","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S0166-2236(00)02002-6","article-title":"The sleep switch: hypothalamic control of sleep and wakefulness.","volume":"24","author":"Saper","year":"2001","journal-title":"Trends Neurosci"},{"key":"R192-1-20210211","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1136\/jnnp.2005.065870","article-title":"Modafinil for daytime somnolence in Parkinsons disease: double blind, placebo controlled parallel trial.","volume":"76","author":"Ondo","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R193-1-20210211","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/mds.870130606","article-title":"A community-base study of sleep disorders in patients with Parkinsons disease.","volume":"13","author":"Tanberg","year":"1998","journal-title":"Mov Disord"},{"key":"R194-1-20210211","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1212\/WNL.58.10.1544","article-title":"Development of daytime somnolence over time in Parkinsons disease.","volume":"58","author":"Gjerstad","year":"2002","journal-title":"Neurology"},{"key":"R195-1-20210211","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1212\/01.wnl.0000183056.89590.0d","article-title":"Excessive daytime sleepiness and subsequent development of Parkinson disease.","volume":"65","author":"Abbott","year":"2005","journal-title":"Neurology"},{"key":"R196-1-20210211","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1212\/WNL.58.7.1019","article-title":"Parkinsons disease and sleepiness: an integral part of PD.","volume":"58","author":"Arnulf","year":"2002","journal-title":"Neurology"},{"key":"R197-1-20210211","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1365-2869.2000.00201.x","article-title":"FAST TRACK: daytime sleepiness in Parkinsons disease.","volume":"9","author":"Rye","year":"2000","journal-title":"J Sleep Res"},{"key":"R198-1-20210211","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/mds.10167","article-title":"Sleep disorders in Parkinsons disease.","volume":"17","author":"Kumar","year":"2002","journal-title":"Mov Disord"},{"key":"R199-1-20210211","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/archneur.61.1.97","article-title":"Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older(ergot) vs new (nonergot) dopamine agonists.","volume":"61","author":"Razmy","year":"2004","journal-title":"Arch Neurol"},{"key":"R200-1-20210211","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/sleep\/27.5.967","article-title":"Daytime sleepiness and alertness in patients with Parkinson disease.","volume":"27","author":"Steven","year":"2004","journal-title":"Sleep"},{"key":"R201-1-20210211","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1001\/archneur.62.8.1242","article-title":"Sudden uncontrollable somnolence and medication use in Parkinsons disease.","volume":"62","author":"Avorn","year":"2005","journal-title":"Arch Neurol"},{"key":"R202-1-20210211","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1212\/01.wnl.0000258660.74391.c1","article-title":"Ropinorole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.","volume":"68","author":"Pahwa","year":"2007","journal-title":"Neurology"},{"key":"R203-1-20210211","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S1474-4422(07)70108-4","article-title":"Efficacy of pramipexole and transdermal rotigotine in advanced Parkinsons disease: a double-blind, double-dummy, randomized controlled trial.","volume":"6","author":"Poewe","year":"2007","journal-title":"Lancet Neurol"},{"key":"R204-1-20210211","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/mds.20412","article-title":"Driving in Parkinsons disease: mobility, accidents, and sudden onset of sleep at the wheel.","volume":"20","author":"Meindorfner","year":"2005","journal-title":"Mov Disrod"},{"key":"R205-1-20210211","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s11910-996-0041-8","article-title":"Excessive daytime sleepiness and unintended sleep in Parkinsons disease.","volume":"6","author":"Rye","year":"2006","journal-title":"Cur Neurol Neurosci Rep"},{"key":"R206-1-20210211","first-page":"1337","article-title":"Sodium oxybate for excessive daytime sleepiness in Parkinson disease: an open-label polysomnography study.","volume":"65","author":"OndoWG Perkins","year":"2008","journal-title":"Arch neurol"},{"key":"R207-1-20210211","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1136\/jnnp.2006.100016","article-title":"Improvement of gait by chronic high dose of methylphenidate in patients with advanced Parkinsons disease.","volume":"78","author":"Devos","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R208-1-20210211","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.nbd.2007.12.003","article-title":"An inverse agonist of the histamine H (3) receptor improves wakefulness in narcolepsy: studies in orexin mice and patients.","volume":"30","author":"Lin","year":"2008","journal-title":"Neurobiol Dis"},{"key":"R209-1-20210211","doi-asserted-by":"crossref","first-page":"s204","DOI":"10.1016\/S0924-977X(09)70268-8","article-title":"Result of clinical trials of tiprolisant in narcolepsy and Parkinsons disease.","volume":"19","author":"Arnulf","year":"2009","journal-title":"Eur Neuropsychopharmacol"},{"key":"R210-1-20210211","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/mds.10390","article-title":"Randomized trial of modafinil for treating subjective daytime sleepiness.","volume":"18","author":"Adler","year":"2003","journal-title":"Mov Disord"},{"key":"R211-1-20210211","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/sleep\/25.8.62","article-title":"Madafinil for the treatment of daytime sleepiness in Parkinsons disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial.","volume":"25","author":"Hogl","year":"2002","journal-title":"Sleep"},{"key":"R212-1-20210211","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s002210000370","article-title":"Antiparkinsonian and neuroprotective effects of modafinil in mptp-treated common marmoset.","volume":"133","author":"Jenner","year":"2000","journal-title":"Exp Brain Res"},{"key":"R213-1-20210211","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1111\/j.1468-1331.2008.02167.x","article-title":"Pedunculopontine nucleus stimulation influences REM sleep in Parkinsons disease.","volume":"15","author":"Romigi","year":"2008","journal-title":"Eur Neurol"},{"key":"R214-1-20210211","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/mds.10307","article-title":"Restless leg syndrome in Parkinsons disease: a case-controlled study.","volume":"18","author":"Krish","year":"2003","journal-title":"Mov Disord"},{"key":"R215-1-20210211","first-page":"421","article-title":"Exploring the relationship between Parkinson disease and restless leg syndrome.","volume":"59","author":"Ondo","year":"2002","journal-title":"Ach Neurol"},{"key":"R217-1-20210211","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0022-510X(02)00020-5","article-title":"Restless leg syndrome in Parkinsons disease.","volume":"196","author":"Tan","year":"2002","journal-title":"J Neurol Sci"},{"key":"R218-1-20210211","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1002\/mds.22694","article-title":"Restless leg syndrome in Parkinsons disease.","volume":"24","author":"Peralta","year":"2009","journal-title":"Mov Disord"},{"key":"R219-1-20210211","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1212\/WNL.57.7.1307","article-title":"Normal IPT and IBZM SPECT in drug-naive and levodopa-treated idiopathic restless leg syndrome.","volume":"57","author":"Eisensehr","year":"2001","journal-title":"Neurology"},{"key":"R220-1-20210211","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/PL00007859","article-title":"SPECT imaging of striatal pre and postsynaptic dopaminergic status in restless leg syndrome with periodic limb movement in sleep.","volume":"249","author":"Michaud","year":"2002","journal-title":"J Neurol"},{"key":"R221-1-20210211","first-page":"107","article-title":"Sleep dysfunction in Parkinsons disease.","volume":"5","author":"Trenkwalder","year":"1998","journal-title":"Clin Neurosci"},{"key":"R222-1-20210211","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0733-8619(05)70286-3","article-title":"Sleep and degenerative neurologic disorders.","volume":"14","author":"Chokroverty","year":"1996","journal-title":"Neurologic Clinics"},{"key":"R223-1-20210211","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00415-003-0957-8","article-title":"Periodic leg movement in patients with Parkinsons disease are associated with reduced striatal dopamine transporter binding.","volume":"250","author":"Happe","year":"2003","journal-title":"J Neurol"},{"issue":"suppl 18","key":"R224-1-20210211","first-page":"S466","article-title":"Stage of the art in restless legs syndrome: practice recommendations for treating restless legs syndrome.","volume":"22","author":"Oretal","year":"2007","journal-title":"Mov Disord"},{"key":"R225-1-20210211","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1111\/j.1468-1331.2006.01410.x","article-title":"EFNS guidelines on management of restless legs syndrome and periodic limb movement disorder in sleep.","volume":"13","author":"Vignatelli","year":"2006","journal-title":"Eur J Neurol"},{"key":"R226-1-20210211","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.sleep.2006.03.011","article-title":"Efficacy and safety of pramipexole in idiopathic restless leg syndrome: a polysomnographic dose-finding study-The PRELUDE study.","volume":"7","author":"Partinen","year":"2006","journal-title":"Sleep Med"},{"key":"R227-1-20210211","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/mds.21050","article-title":"Ropinorole is effective in the long-term management of restless leg syndrome: a randomized controlled trial.","volume":"21","author":"Montplaisir","year":"2006","journal-title":"Mov Disord"},{"key":"R228-1-20210211","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1212\/WNL.52.5.938","article-title":"Pramipexol alleviates sensory and motor symptoms of restless leg syndrome.","volume":"52","author":"Montplaisir","year":"1998","journal-title":"Neurology"},{"key":"R229-1-20210211","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/mds.21261","article-title":"Efficacy of pramipexole in restless leg syndrome: a six-week, multicenter, randomized, double-blind study (effect-RLS study).","volume":"22","author":"Oertel","year":"2007","journal-title":"Mov Disord"},{"key":"R230-1-20210211","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/mds.22254","article-title":"Treatment of restless leg syndrome: an evidenced-base review and implications for clinical practice.","volume":"23","author":"Trenkwalder","year":"2008","journal-title":"Mov Disord"},{"key":"R231-1-20210211","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/sleep\/27.5.907","article-title":"Ropinirole decrease periodic limb movements and improves sleep parameters in patients with restless leg syndrome.","volume":"27","author":"Allen","year":"2004","journal-title":"Sleep"},{"key":"R232-1-20210211","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.sleep.2006.09.009","article-title":"A 52-week open label study of the long-term safety of ropinorole in patients with restless leg syndrome.","volume":"8","author":"Garcia-Borreguero","year":"2007","journal-title":"Sleep Med"},{"key":"R233-1-20210211","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S1474-4422(08)70112-1","article-title":"Efficacy of rotigotine for treatment of moderate-to-severe restless leg syndrome: a randomized double-blind, placebo-controlled.","volume":"7","author":"Trenkwalter","year":"2008","journal-title":"Lancet Neurol"},{"key":"R234-1-20210211","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/mds.23157","article-title":"Rotigotine improves restless leg syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States.","volume":"25","author":"Hening","year":"2010","journal-title":"Mov Disord"},{"key":"R235-1-20210211","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.sleep.2008.11.003","article-title":"Efficacy of oral iron in patients with restless leg syndrome and a low-normal ferritin: a randomized double-blind, placebo-controlled study.","volume":"10","author":"Wang","year":"2009","journal-title":"Sleep Med"},{"key":"R237-1-20210211","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0954-6111(03)00188-4","article-title":"Sleep breathing disorders in patients with idiopathic Parkinsons disease.","volume":"97","author":"Maria","year":"2003","journal-title":"Respir Med"},{"key":"R238-1-20210211","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1212\/WNL.51.2.526","article-title":"Sleep-related violence, injury, and REM sleep behavior disorder in Parkinsons disease.","volume":"51","author":"Comella","year":"1998","journal-title":"Neurology"},{"key":"R239-1-20210211","first-page":"513","article-title":"Sleep-related injury in elderlyan epidemiological study in Hongkong.","volume":"15","author":"Chiu","year":"2000","journal-title":"Sleep"},{"key":"R240-1-20210211","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/brain\/awl363","article-title":"Restoration of normal motor control in Parkinsons disease during REM sleep.","volume":"130","author":"De Cook","year":"2007","journal-title":"Brain"},{"key":"R241-1-20210211","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1212\/01.wnl.0000233926.47469.73","article-title":"Update on the pharmacology of REM sleep behavior disorder.","volume":"67","author":"Gagnon","year":"2006","journal-title":"Neurology"},{"key":"R242-1-20210211","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/sleep\/25.2.120","article-title":"REM sleep behavior disorder: clinical, developmental, and neuroscience perspectives 16 years after its formal identification in SLEEP.","volume":"25","author":"Schenck","year":"2002","journal-title":"Sleep"},{"key":"R245-1-20210211","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1212\/WNL.0b013e3181ca0166","article-title":"Severity of RM atonia loss in idiopathic REM sleep behavior disorder predicts Parkinson disease.","volume":"74","author":"Postuma","year":"2010","journal-title":"Neurology"},{"key":"R246-1-20210211","first-page":"A316Abs","article-title":"REM sleep behavior disorder (RBD): delayed emergence of parkinsonism andor dementia is 65 of older men initially diagnosed with idiopathic RBD, and an analysis of the minimum maximum tonic andor phasic electromyographic abnormalities found during REM sleep.","volume":"26","author":"Schenck","year":"2003","journal-title":"Sleep"},{"key":"R247-1-20210211","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S1474-4422(06)70476-8","article-title":"Rapid-eye movement sleep behavior disorder as an early marker for a neurodegenerative disorder: a descriptive study.","volume":"5","author":"Iranzo","year":"2006","journal-title":"Lancet Neurol"},{"key":"R248-1-20210211","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1212\/01.wnl.0000168864.97813.e0","article-title":"Characteristics of idiopathic REM sleep behavior disorder and that associated with MSA and PD.","volume":"65","author":"Iranzo","year":"2005","journal-title":"Neurology"},{"key":"R249-1-20210211","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/mds.1120","article-title":"Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy.","volume":"16","author":"Boeve","year":"2001","journal-title":"Mov Disord"},{"key":"R250-1-20210211","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/brain\/123.2.331","article-title":"Rapid-eye movement sleep behavior disorder: demographic, clinical, and laboratory finding in 93 cases.","volume":"123","author":"Olson","year":"2000","journal-title":"Brain"},{"key":"R251-1-20210211","first-page":"349","article-title":"REM sleep behavior disorder and REM sleep without atonia in patient with progressive supranuclear gaze palsy.","volume":"28","author":"Arnulf","year":"2005","journal-title":"Sleep"},{"key":"R252-1-20210211","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/sleep\/20.10.891","article-title":"Subclinical REM sleep behavior disorder in patient with corticobasal degeneration.","volume":"20","author":"Kimura","year":"1997","journal-title":"Sleep"},{"key":"R253-1-20210211","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1468-1331.2002.00335.x","article-title":"Homozygous Machado-Joseph disease presenting as REM sleep behavior disorder and prominent psychiatric symptoms.","volume":"9","author":"Fukutake","year":"2002","journal-title":"Eur Neurol"},{"key":"R254-1-20210211","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1212\/WNL.60.1.148","article-title":"REM sleep behavior disorder and SCA-3 (Machado-Joseph disease).","volume":"60","author":"Syed","year":"2003","journal-title":"Neurology"},{"key":"R255-1-20210211","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/sleep\/29.10.1321","article-title":"REM sleep behavior disorder and REM sleep without atonia in propable Alzheimer disease.","volume":"29","author":"Gagnon","year":"2006","journal-title":"Sleep"},{"key":"R256-1-20210211","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinsons disease.","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol Aging"},{"key":"R257-1-20210211","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.clineuro.2005.03.011","article-title":"Brainstem 1H-MR spectroscopy in patients with Parkinsons disease with REM sleep behavior disorder and IPD patients without dream enactment behavior.","volume":"108","author":"Hanoglu","year":"2006","journal-title":"Clin Neurol Neurosurg"},{"key":"R258-1-20210211","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1002\/mds.22099","article-title":"Manifestation of Parkinson disease differ in association with REM sleep behavior disorder.","volume":"12","author":"Postuma","year":"2008","journal-title":"Mov Disord"},{"key":"R259-1-20210211","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2869.1993.tb00093.x","article-title":"Symposium: normal and abnormal REM sleep regulation: REM sleep behavior disorder: an update on a series of 96 patients and a review of the world literature.","volume":"2","author":"Schenck","year":"1993","journal-title":"J Sleep Res"},{"key":"R260-1-20210211","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/brain\/123.2.331","article-title":"Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases.","volume":"123","author":"Olson","year":"2000","journal-title":"Brain"},{"key":"R261-1-20210211","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1389-9457(03)00072-8","article-title":"Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients.","volume":"4","author":"Boeve","year":"2003","journal-title":"Sleep Med"},{"key":"R262-1-20210211","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1017\/S135561770606111X","article-title":"Faces of emotion in Parkinsons disease: micro-expressivity and bradykinesia during voluntary facial expressions.","volume":"12","author":"Bowers","year":"2006","journal-title":"J Int Neuropsychol Soc"},{"key":"R264-1-20210211","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1037\/a0016105","article-title":"The influence of facial masking and sex on older adults impressions of individuals with Parkinsons disease.","volume":"24","author":"Hemmesch","year":"2009","journal-title":"Psychol Aging"},{"key":"R265-1-20210211","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1460-9568.2009.06892.x","article-title":"Neuroanatomical correlates of impaired decision-making and facial emotion recognition in early Parkinsons disease.","volume":"30","author":"Ibarretxe-Bilbao","year":"2009","journal-title":"Eur J Neurosci"},{"key":"R266-1-20210211","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1002\/mds.22246","article-title":"Prevalence and correlates of neuropsychiatric symptoms in Parkinsons disease without dementia.","volume":"23","author":"Kulisevsky","year":"2008","journal-title":"Mov Disord"},{"key":"R267-1-20210211","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1212\/WNL.45.9.1696","article-title":"Emotional facial imagery, perception, and expression in Parkinsons disease.","volume":"45","author":"Jacobs","year":"1995","journal-title":"Neurology"},{"key":"R268-1-20210211","first-page":"131","article-title":"Perceptual characteristics of Parkinsonian speech: a comparison of the pharmacological effects of levodopa across speech and non-speech motor systems.","volume":"24","author":"Plowman-Prine","year":"2009","journal-title":"Neuro Rehabilitation"},{"key":"R269-1-20210211","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/mds.21899","article-title":"For better or worse: the effect of levodopa on speech in Parkinsons disease.","volume":"23","author":"Ho","year":"2008","journal-title":"Mov Disord"},{"key":"R270-1-20210211","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00221-009-2048-2","article-title":"Laryngeal somatosensory deficits in Parkinsons disease: implications for speech respiratory and phonatory control.","volume":"201","author":"Hammer","year":"2010","journal-title":"Exp Brain Res"},{"key":"R271-1-20210211","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/mds.22430","article-title":"Progression of dysprosody in Parkinsons disease over timea longitudinal study.","volume":"24","author":"Skodda","year":"2009","journal-title":"Mov Disord"},{"key":"R272-1-20210211","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1037\/a0018104","article-title":"A meta-analysis of performance on emotion recognition tasks in Parkinsons disease.","volume":"24","author":"Gray","year":"2010","journal-title":"Neuropsychology"},{"key":"R273-1-20210211","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1017\/S1355617709990919","article-title":"Listener impressions of speakers with Parkinsons disease.","volume":"16","author":"Jaywant","year":"2010","journal-title":"J Int Neuropsychol Soc"},{"key":"R274-1-20210211","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jcomdis.2009.07.004","article-title":"Voice onset time in Parkinson disease.","volume":"43","author":"Fischer","year":"2010","journal-title":"J Commun Disord"},{"key":"R275-1-20210211","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S1474-4422(04)00854-3","article-title":"Treatments for dysarthria in Parkinsons disease.","volume":"3","author":"Pinto","year":"2004","journal-title":"Lancet Neurol"},{"key":"R276-1-20210211","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/hbm.20859","article-title":"Neural correlates of efficacy of voice therapy in Parkinsons disease identified by performance-correlation analysis.","volume":"31","author":"Narayana","year":"2010","journal-title":"Hum Brain Mapp"},{"key":"R277-1-20210211","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1055\/s-2004-825653","article-title":"Parkinsons disease: speech and voice disorders and their treatment with the Lee Silverman Voice Treatment.","volume":"25","author":"Ramig","year":"2004","journal-title":"Semin Speech Lang"},{"key":"R278-1-20210211","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/mds.22989","article-title":"Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinsons disease.","volume":"25","author":"Friedman","year":"2010","journal-title":"Mov Disord"},{"key":"R279-1-20210211","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/mds.1201","article-title":"Fatigue in Parkinsons disease: a nine-year follow-up.","volume":"16","author":"Friedman","year":"2001","journal-title":"Mov Disord"},{"key":"R280-1-20210211","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1468-1331.2008.02103.x","article-title":"Impact of fatigue on quality of life in patients with Parkinsons disease.","volume":"15","author":"Havlikova","year":"2008","journal-title":"Eur J Neurol"},{"key":"R281-1-20210211","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1002\/mds.21656","article-title":"Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial.","volume":"22","author":"Mendonca","year":"2007","journal-title":"Mov Disord"},{"key":"R282-1-20210211","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/WNF.0b013e3181aa916a","article-title":"Using modafinil to treat fatigue in Parkinson disease: a double-blind, placebo-controlled pilot study.","volume":"32","author":"Lou","year":"2009","journal-title":"Clin Neuropharmacol"},{"key":"R283-1-20210211","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s00415-009-5351-8","article-title":"Modafinil for Parkinsons disease fatigue.","volume":"257","author":"Tyne","year":"2010","journal-title":"J Neurol"},{"key":"R284-1-20210211","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1001\/archneur.65.10.1337","article-title":"Sodium oxybate for excessive daytime sleepiness in Parkinson disease: an open-label polysomnographic study.","volume":"65","author":"Ondo","year":"2008","journal-title":"Arch Neurol"},{"key":"R285-1-20210211","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1002\/mds.22731","article-title":"Fatigue in Japanese patients with Parkinsons disease: a study using Parkinson fatigue scale.","volume":"24","author":"Okuma","year":"2009","journal-title":"Mov Disord"},{"issue":"suppl 7","key":"R286-1-20210211","first-page":"VII38","article-title":"Weight loss in Parkinsons disease.","volume":"253","author":"Kashihara","year":"2006","journal-title":"J Neurol"},{"key":"R287-1-20210211","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/mds.22466","article-title":"Weight loss, body fat mass, and leptin in Parkinsons disease.","volume":"24","author":"Lorefalt","year":"2009","journal-title":"Mov Disord"},{"key":"R288-1-20210211","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1017\/S031716710000175X","article-title":"Respiratory muscle performance and the perception of dyspnea in Parkinsons disease.","volume":"29","author":"Weiner","year":"2002","journal-title":"Can J Neurol Sci"},{"key":"R289-1-20210211","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1017\/S0317167100003991","article-title":"Inspiratory muscle training and the perception of dyspnea in Parkinsons disease.","volume":"32","author":"Inzelberg","year":"2005","journal-title":"Can J Neurol Sci"}],"container-title":["The Neurologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/NRL.0b013e31823d7abb","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:24:43Z","timestamp":1742257483000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00127893-201201000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":272,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/nrl.0b013e31823d7abb","relation":{},"ISSN":["1074-7931"],"issn-type":[{"value":"1074-7931","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}